Table 1.
Clinical information, laboratory findings, and treatment strategies.
| Prior to 2nd Dose | Initial Diagnosis | Follow-Up | Relapse | Normal Range | |
|---|---|---|---|---|---|
| Date | 5 July 2021 | 10 August 2021 | - | 17 February 2022 | |
| Clinical manifestations | - | Hemoptysis, dyspnea, fever | - | fever | |
| Serum creatinine (mg/dL) | 1.01 | 3.45 | 1.2 | 1.7 | 0.5–1.2 |
| BUN (mg/dL) | 36 | 170 | 65 | 83 | 10–40 |
| MPO ANCA (U/mL) | - | 20.3 | 7.1 | 27.6 | 0–5.5 |
| Urine sediment | |||||
| RBC (/hpf) | 1–2 | >100 | 2–4 | 26–35 | 1–2 |
| WBC (/hpf) | 1–2 | 16–25 | 2–4 | 26–35 | 1–2 |
| Proteinuria (mg/24 h) | - | 2052 | 576 | 1106 | <150 |
| Pulmonary hemorrhage | - | YES | - | NO | |
| Renal-replacement therapy | - | NO | - | NO | |
| AAV treatment | - | IV steroids+ IV CYC | po steroids+ IV CYC | IV steroids+ IV CYC |
Abbreviations: AAV, ANCA-associated vasculitis; ANCA, Antineutrophil Cytoplasmic Antibodies; BUN, blood urea nitrogen; MPO, myeloperoxidase; RBC, red-blood count; WBC, white-blood count, IV, intravenous; po, per os; CYC, cyclophospamide.